Rob Stein

Copyright 2021 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

As the climate changes, our seasons are changing, too.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

Kelly LaDue thought she was done with COVID-19 in the fall of 2020 after being tormented by the virus for a miserable couple of weeks.

"And then I started with really bad heart-racing with any exertion. It was weird," says LaDue, 54, of Ontario, N.Y. "Walking up the stairs, I'd have to sit down and rest. And I was short of breath. I had to rest after everything I did."

The number of people getting COVID-19 vaccine boosters in the U.S. is now far outpacing the number getting their first shots, according to the Centers for Disease Control and Prevention.

That trend represents a big success for White House's aggressive booster campaign. But it also underscores the administration's flagging effort to achieve its high priority of vaccinating the remaining unvaccinated Americans.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

SCOTT DETROW, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

SCOTT DETROW, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

SCOTT DETROW, HOST:

Updated Oct. 14, 12:45 p.m. ET

If you got the Johnson & Johnson vaccine as your first COVID-19 shot, a booster dose of either the Moderna or Pfizer-BioNTech vaccine apparently could produce a stronger immune response than a second dose of J&J's vaccine. That's the finding of a highly anticipated study released Wednesday.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

A MARTINEZ, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

A MARTINEZ, HOST:

For the first time, doctors are reporting that they have restored vision to people blinded by a rare genetic disorder using the revolutionary gene-editing technique known as CRISPR.

Carlene Knight's vision was so bad that she couldn't even maneuver around the call center where she works using her cane.

"I was bumping into the cubicles and really scaring people that were sitting at them," says Knight, who was born with a rare genetic eye disease.

But that's changed as a result of volunteering for a landmark medical experiment. Her vision has improved enough for her to make out doorways, navigate hallways, spot objects and even see colors.

"It's nice. I don't scare people and I don't have as many bruises on my body," Knight says, laughing.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

STEVE INSKEEP, HOST:

Americans may be able to breathe a tentative sigh of relief soon, according to researchers studying the trajectory of the pandemic.

The delta surge appears to be peaking nationally, and cases and deaths will likely decline steadily now through the spring without a significant winter surge, according to a new analysis shared with NPR by a consortium of researchers advising the Centers for Disease Control and Prevention.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

RACHEL MARTIN, HOST:

The pharmaceutical company Johnson & Johnson now says a booster shot to its COVID vaccine will improve immunity. Joining us now with details - NPR health correspondent Rob Stein. Good morning, Rob.

A head-to-head comparison of all three COVID-19 vaccines found Moderna is holding up better than Pfizer and the Johnson & Johnson vaccine provides the weakest protection.

But the researchers stressed that all three vaccines are still providing strong protection against people getting so sick that they end up in the hospital.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

A MARTINEZ, HOST:

Like millions of others, Kathleen Hipps thought she was safe from COVID-19 after she got two shots of the Moderna vaccine last spring. So she figured she just had a summer cold when she got the sniffles in July. But then she opened some Vick's VapoRub.

"Anyone who's ever smelled Vick's VapoRub knows how pungent of a smell it is. And I couldn't smell it. And that's how I knew I had COVID," says Hipps, 40, a Los Angeles lawyer who has two young sons.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

LEILA FADEL, HOST:

Johnson & Johnson says it has evidence that people who got the company's COVID-19 vaccine could benefit from a booster. NPR health correspondent Rob Stein joins us now with the details. Hi, Rob.

ROB STEIN, BYLINE: Good morning.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

LEILA FADEL, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

STEVE INSKEEP, HOST:

An internal slide presentation from the Centers for Disease Control and Prevention dated Thursday gives new details on how dangerous the delta variant really is.

One chart shows that it could be as contagious as chickenpox, which is one of the more transmissible viruses out there. It spreads more easily than the common cold, the 1918 flu and smallpox.


There's more potentially worrisome news for vaccinated people: In very rare cases, people experiencing breakthrough infections may be at risk for long-COVID symptoms.

That's according to a small new study of fully vaccinated health care workers in Israel, published Wednesday in The New England Journal of Medicine.

For the first time, scientists have shown that a new kind of genetic engineering can crash populations of malaria-spreading mosquitoes.

In the landmark study, published Wednesday in the journal Nature Communications, researchers placed the genetically modified mosquitoes in a special laboratory that simulated the conditions in sub-Saharan Africa, where they spread the deadly disease.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Updated July 29, 2021 at 12:05 PM ET

This story has been updated throughout to reflect new research.

New data on the delta variant is coming in, and it's not looking good. The currently authorized vaccines are still very protective, especially against hospitalization and death. But when it comes to getting an asymptomatic or mild case of COVID-19, they may not be quite as protective as they were against earlier strains.

Updated July 9, 2021 at 2:05 PM ET

As the weather warmed up this year, coronavirus case numbers plummeted, and life in the U.S. started to feel almost normal. But in recent weeks, that progress has stalled.

The vaccination campaign has slowed, and the delta variant is spreading rapidly. And new infections, which had started to plateau about a month ago, are going up slightly nationally.

The highly contagious delta variant now accounts for more than 51% of COVID-19 cases in the U.S., according to new estimates released by the Centers for Disease Control and Prevention. The variant, also known as B.1.617.2, was first detected in India and is spreading quickly across the globe.

And in parts of the U.S., the delta strain accounts for more than 80% of new infections, including some Midwestern states such as Missouri, Kansas and Iowa.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

The federal government announced today that it is deploying special COVID-19 surge response teams to try to snuff out new hotspots that are emerging around the country. NPR health correspondent Rob Stein joins us with details. Hi, Rob.

Pages